PreveCeutical Medical Inc. (CSE:PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”) announces an update on the Company’s due diligence on the Penta 5 group of companies
PreveCeutical Medical Inc. (CSE:PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”) announces an update on the Company’s due diligence on the Penta 5 group of companies (the “Penta 5 Group”), in connection with the proposed acquisition by the Company of the Penta 5 Group (the “Acquisition”) and its assets, which include over seven brands, 40 market-ready products, previously announced on October 3, 2018.
To advance the due diligence process, the Company’s management team has scheduled a due diligence trip (the “Due Diligence Trip”) to the Penta 5 Group’s leased 150,000 square foot state-of-the-art packaging facility (the “Facility”) located in Sarasota, Florida, used for the packaging of food and beverages, non-food items and hemp products. The Due Diligence Trip will include a tour of the Facility’s FDA approved filling and packing rooms, sealing machinery and bonded warehouse, as well as the full range of low and high-speed production lines.
Mr. Stephen Van Deventer, PreveCeutical’s Chairman, CEO and President, stated, “We are happy with the results of our due diligence to date and are now ready to conduct an on-site inspection of the Penta 5 Group’s operations. I am excited to understand the full scope of the Penta 5 facility’s diverse capabilities and determine how it can be applied to the future growth of PreveCeutical.”
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a Sol-gel drug delivery program; Nature IdenticalTM peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on PreveCeutical’s website.
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
For further information, please contact:
PREVECEUTICAL MEDICAL INC.
Director of Corporate Communications & Investor Relations
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the results of the Company’s due diligence on the Penta 5 Group; the completion of the Acquisition; the ability of the Company to commercialize the Penta 5 Group’s products; the manufacture and sale of the Company’s current and future products; the efficacy of the Company’s products, generally; matters related to the Company’s current and planned research and development programs; the anticipated benefits of the Acquisition; the Company’s anticipated business plans; and the prospect of its ability and success in executing its proposed plans. Forward-looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations, performance, industry trends and growth opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations, including Canadian Securities Exchange acceptance of the Acquisition; complete the Acquisition; continue its research programs; and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the healthcare, cannabis, biotechnology, pharmaceutical or packaging industries, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.